Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Target in Triple-Negative Breast Cancer

A New Target in Triple-Negative Breast Cancer

Triple-negative breast cancer accounts for approximately 10-15% of all breast cancers. Unlike other invasive breast cancer types, triple-negative breast cancer grows more quickly and is not treated with the hormonal therapies used in breast cancer or HER2-targeted drugs. The word “triple” in triple-negative breast cancer means that it lacks the estrogen, progesterone and HER2 receptors targeted in other breast cancers.

what are the types of breast cancer hormone positive her2 negative triple

New research from a cancer institute in Toronto offers hope for this triple-negative breast cancer. The researchers state that they have found a new protein biomarker and could thereby improve targeted therapy effectiveness.

Mathieu Lupien, a member of the research team, explains the study's purpose and importance: “Unfortunately, a treatment providing a definitive solution for this patient group does not exist. Because there is no identified treatment target, patients are treated with chemotherapy and, much more recently, immunotherapy. Although initially effective in some patients, about one-quarter develop disease recurrence and chemotherapy resistance within 5 years of diagnosis. Identifying new biomarkers and treatments is extremely important for this breast cancer type, which causes death in more than 30% of patients because of this resistance. In our studies, in triple-negative breast cancer cell lines, we found that the glucose transporter 1 (GLUT1) protein is produced in large amounts. We then examined its effect on cancer cells using drug-like compounds that inhibit this protein's function. We also found that a protein with a tumor-suppressor role, RB1, is also involved in this mechanism ”.

Study results and significance

The researchers conducting the study reported that, in cancer cells producing large amounts of RB1 protein, the drug-like molecule that inhibits the GLUT1 protein stops tumor growth. Inhibiting the function of GLUT1 proteins, which allow glucose essential for survival to flow into cells, makes cancer cells more sensitive to anticancer drugs and provides a good target for a new treatment.

Observing that cells not producing RB1 protein were not sensitive to the agent inhibiting GLUT1 protein, the researchers particularly emphasize that RB1 protein is an important indicator of response to GLUT1-targeted therapy and must be used to identify patients who will respond.

These studies are highly important for targeted therapies, which have recently been used in many different cancer types with very successful results. As the biology of triple-negative breast cancer is better understood, the development of more successful treatments will be inevitable.

Sources

Wu, Q., ba-alawi, W., Deblois, G. et al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nat Commun 11, 4205 (2020). https://doi.org/10.1038/s41467-020-18020-8

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Target in Triple-Negative Breast Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy